University of Pittsburgh researchers launching trial of new osteoporosis drug

Jan 14, 2010

Endocrinologists at the University of Pittsburgh School of Medicine and UPMC are launching a human trial of a new drug that their research indicates holds great promise for building bones weakened by osteoporosis.

For the study, 105 participants will be randomly assigned to receive either teriparitide ( Forteo®), a drug that already is FDA-approved for osteoporosis treatment, or an experimental agent called hormone-related protein (PTHrP), explained principal investigator Mara J. Horwitz, M.D., an assistant Professor of Medicine in the Division of Endocrinology and Metabolism, Pitt School of Medicine, and a practicing metabolic specialist at UPMC.

"We are very eager to find out how this new drug compares to a therapy that is currently available," Dr. Horwitz said. "Our previous studies suggest that it may increase more dramatically with fewer side effects, but this is the first head-to-head comparison."

On the cellular level, bone is constantly being broken down, a process known as resorption, and then rebuilt. In osteoporosis, this balancing act is off-kilter, leaving bones less dense and more vulnerable to fracture. Many drugs, such as alendronate (Fosamax®), and raloxifene (Evista®), work by decreasing . They can improve bone density by two to 10 percent over several years to a decade and reduce fractures, but many patients' bone density already has been reduced by half when treatment begins.

Another kind of agent works on the other end of the see-saw: it promotes the creation of new bone. Teriparitide, a form of naturally occurring parathyroid hormone, currently is the only FDA-approved anabolic or bone-building agent in the United States. The PTHrP, another protein made naturally by the body, also is an anabolic agent and appears to be unique in its ability to stimulate without simultaneously increasing bone breakdown. Both drugs are given as daily injections.

"When we studied PTHrP several years ago in small numbers of postmenopausal women with , we found that bone density increased by nearly 5 percent after only three months of treatment," said senior investigator Andrew F. Stewart, M.D., professor and chief of the Division of Endocrinology and Metabolism, Department of Medicine, Pitt School of Medicine. "And even at the highest doses, the side effects were negligible."

In findings published online last week in the Journal of Clinical Endocrinology and Metabolism, Drs. Horwitz and Stewart and their colleagues identified the maximum tolerable dose and therapeutic window of PTHrP. In this study, they were also able to show that PTHrP, at the tolerable doses, stimulated bone formation after only three weeks of treatment.

Explore further: More than a quarter of emergency contraceptives in Peru falsified or substandard

Provided by University of Pittsburgh

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Procedure developed at Yale creates new bone

Feb 14, 2008

A new technique that combines bone marrow removal and injection of a hormone helps promote rapid formation of new bone at targeted locations in the body, it was reported by Yale School of Medicine this month in Tissue En ...

Recommended for you

Study recalculates costs of combination vaccines

Apr 17, 2014

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

Apr 17, 2014

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

User comments : 0

More news stories

Treating depression in Parkinson's patients

A group of scientists from the University of Kentucky College of Medicine and the Sanders-Brown Center on Aging has found interesting new information in a study on depression and neuropsychological function in Parkinson's ...

Airbnb rental site raises $450 mn

Online lodging listings website Airbnb inked a $450 million funding deal with investors led by TPG, a source close to the matter said Friday.

Health care site flagged in Heartbleed review

People with accounts on the enrollment website for President Barack Obama's signature health care law are being told to change their passwords following an administration-wide review of the government's vulnerability to the ...